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Efficacy of anidulafungin is driven by the area under the concentration-time curve (AUC)/MIC ratio. Determination of the
anidulafungin AUC along withMIC values can therefore be useful. Since obtaining a full concentration-time curve to determine
an AUC is not always feasible or appropriate, limited-sampling strategies may be useful in adequately estimating exposure. The
objective of this study was to develop a model to predict the individual anidulafungin exposure in critically ill patients using lim-
ited-sampling strategies. Pharmacokinetic data were derived from 20 critically ill patients with invasive candidiasis treated with
anidulafungin. These data were used to develop a two-compartment model in MWPharm using an iterative 2-stage Bayesian
procedure. Limited-sampling strategies were subsequently investigated using twomethods, a Bayesian analysis and a linear re-
gression analysis. The best possible strategies for these twomethods were evaluated by a Bland-Altman analysis for correlation
of the predicted and observed AUC from 0 to 24 h (AUC0–24) values. Anidulafungin exposure can be adequately estimated with
the concentration from a single sample drawn 12 h after the start of the infusion either by linear regression (R2 0.99; bias,
0.05%; root mean square error [RMSE], 3%) or using a population pharmacokinetic model (R2 0.89; bias,0.1%; RMSE, 9%)
in critically ill patients and also in less severely ill patients, as reflected by healthy volunteers. Limited sampling can be advanta-
geous for future studies evaluating the pharmacokinetics and pharmacodynamics of anidulafungin and for therapeutic drug
monitoring in selected patients. (This study has been registered at ClinicalTrials.gov under registration no. NCT01047267.)
Echinocandins are a valuable addition for the treatment of in-vasive fungal infections, as they are efficacious, demonstrate
low toxicity, and have limited drug-drug interactions (1).
The area under the concentration-time curve (AUC) divided
by the MIC appears to be a good predictor of the efficacy of
echinocandin drugs in a neutropenic murine disseminated-can-
didiasis model (2, 3). No data are available on the influence of the
AUC/MIC ratio on the efficacy and mortality of anidulafungin in
daily practice. More information is necessary to elucidate this re-
lation. Determination of the anidulafungin AUC along with MIC
values is therefore advisable for future research and possibly also
in specific clinical situations, since anidulafungin exposure can be
low in critically ill patients (4). Lack of response to the standard
dose in the situation of an anidulafungin-susceptible tested isolate
may prompt measurement of the anidulafungin concentration to
detect whether drug exposure is too low.
Obtaining a full concentration-time curve to determine an
AUC is not always feasible, since this can be a burden to the pa-
tient, is time-consuming, and is relatively expensive. To overcome
this problem, limited-sampling strategies may be useful in ade-
quately estimating exposure with one or only a few samples. How-
ever, no limited-sampling strategy is available for anidulafungin at
this moment.
The objective of this study was to develop a model to predict
the individual anidulafungin exposure in critically ill patients us-
ing limited sampling strategies.
MATERIALS AND METHODS
Study population. Pharmacokinetic data were derived from patients who
participated in an open-label prospective study on the pharmacokinetics
of anidulafungin in critically ill patients (4). This study was performed in
the University Medical Center Groningen (The Netherlands). Patients
were eligible for inclusion if they were at least 18 years old, admitted to an
intensive care unit, and diagnosed with invasive candidiasis. The study
protocol was approved by the local institutional ethics committee. The
trial was registered at clinicaltrials.gov (NCT01047267). Written in-
formed consent was obtained from each patient or his or her legal repre-
sentative.
The patients were treated with anidulafungin, starting with a loading
dose of 200mg on day one and continuingwith amaintenance dose of 100
mg once daily. On the first day of treatment, blood samples were drawn to
measure anidulafungin plasma concentrations 3 and 12 h after the start of
the 3-h infusion of the loading dose. A concentration-time curve was
obtained at day 3 (1 day) after the start of anidulafungin. Blood samples
were obtained prior to the start of the 1.5-h infusion of anidulafungin and
at 1.5, 2, 3, 4, 6, 8, 12, and 24 h after the start of the infusion. In addition,
blood samples for measuring anidulafungin trough concentrations were
collected every 3 days during the continuation of anidulafungin treatment
in the intensive care unit. All samples were tested with a liquid chroma-
tography-tandem mass spectrometry (LC-MS/MS) method that was val-
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idated according to FDA guidelines for bioanalytical method validation
(5).
Pharmacokinetics. The area under the concentration-time curve
from 0 to 24 h (AUC0–24) was calculated using the log-linear trapezoidal
rule using KINFIT (MWPharm 3.80; Mediware, The Netherlands).
Potential factors that contribute to the pharmacokinetic variability of
anidulafungin were previously investigated (4). A multiple linear regres-
sion analysis provided a significant correlation between anidulafungin
exposure and total body water and bilirubin concentrations. MWPharm
is straightforward software which is user-friendly but lacks the ability to
include an extensive set of influencing factors in themodel. The total body
water was incorporated in themodel by basing themodel on fat-freemass
(FFM), but it was unfortunately not possible to include the bilirubin con-
centration. A two-compartment model based on the observed anidula-
fungin concentrations was created using an iterative 2-stage Bayesian pro-
cedure (6), starting with estimates (clearance [CL], 1.216  0.250 liter/
h/56 kg FFM; central volume of distribution [V1], 0.170 0.041 liter/kg
lean body mass corrected [LBMc]; intercompartmental clearance [Q],
21.6  2.29 liter/h/56 kg FFM; peripheral volume of distribution [V2],
0.392  0.043 liter/kg LBMc) based on those in the literature (7). Inter-
individual variability of the pharmacokinetic parameters was assumed to
be log-normally distributed. The residual error was assumed to be nor-
mally distributed and was modeled as a combination of additive and pro-
portional error. The residual error parameters were estimated during the
analysis. The initial value of both parameters was 0.1.
Limited-sampling strategies.Limited-sampling strategieswere inves-
tigated with two methods: a Bayesian analysis and a linear regression
analysis.
The optimal sampling times were determined with the limited-sam-
pling module of MWPharm based on aMonte Carlo simulation of 1,000
patients randomly drawn from the populationmodel usingBayesian anal-
ysis for parameter estimation. The performance of a strategy was consid-
ered acceptable if the prediction bias was5% and the precision (RMSE)
was 15%. For the most suitable strategy, the AUC0–24 was predicted
using the developed pharmacokinetic model.
For the other method, linear regression analyses were performed in
IBM SPSS Statistics 20 (IBMCorp., Armonk, NY, USA) for the measured
concentrations at every sampling time of the concentration-time curve
versus theAUC0–24. The performance of a strategywas considered accept-
able if the prediction bias was5% and the precision (RMSE)was15%.
TheAUC0–24was predicted using the equation of the regression line of the
most suitable strategy.
Data analysis. The validation of the population pharmacokinetic
model and the linear regression analysis was performed by a cross-valida-
tion in which one patient was left out (n 1). The AUC0–24 of the patient
left out from the developed model was subsequently predicted using this
n  1 model (8). The AUC0–24 predicted with the developed model was
subsequently comparedwith the AUC0–24 predictedwith the n 1model
using a Wilcoxon matched-pair signed-rank test. Means with 90% confi-
dence intervals (CIs) for the ratios of the AUC0–24 predicted with the
developed model and the n 1 model were also calculated.
The best possible limited-sampling strategies for these methods were
evaluated by a Bland-Altman analysis for correlation of predicted and
observed AUC0–24 and by determining the mean with 90% confidence
interval for the ratio of the predicted versus those of the observed anidu-
lafungin exposure as used in bioequivalence tests.
Numerical variables are summarized with medians and interquartile
ranges unless stated otherwise.
External data set. To evaluate if the best possible strategies were also
applicable in less-ill patients receiving anidulafungin, we used data from
healthy volunteers from drug interaction studies (9, 10).
Possible implications for clinical practice. Since the AUC/MIC ratio
is a good predictor of efficacy (2, 3), information about the distribution of
AUCs and MICs is necessary to gain more insight in clinical situations in
which it can be appropriate to determine the anidulafungin exposure.
Data about AUC distribution were available (4). The distributions of
MICs and AUC/MIC ratios were based on EUCAST data (11). The expo-
sure of the general patient population to 110mg · h/liter (12) is accepted to
be sufficient for treating infections with susceptible Candida species (11).
A Candida species was considered susceptible if its MIC was not higher
than the EUCAST clinical breakpoint. Hence, the AUC/MIC target value
is the exposure of the general patient population divided by the clinical
breakpoint. Subsequently, the percentage of patients who achieve the
AUC/MIC ratio target was calculated per MIC.
The median anidulafungin exposure of 65.7 mg · h/liter in our criti-
cally ill patients (4) was lower than the exposure of the general patient
population. An anidulafungin maintenance dose of 170 mg seems appro-
priate to achieve an AUC of 110mg · h/liter for a patient with this median
anidulafungin exposure. This dosewas calculated on the basis of the linear
pharmacokinetics of anidulafungin (1) by dividing theAUCof the general
patient population of 110 mg · h/liter by the achieved AUC and then
multiplying the result by the administered dose (100 mg). A simulation
of this increased dose was made with the pharmacokinetic model in
MWPharm.
RESULTS
Study population.Blood samples were obtained from20 patients,
11male and 9 female, with amedian age of 71 (60 to 75) years and
a body mass index (BMI) of 25.8 (23.4 to 36.4) kg/m2. Patients
received treatment with anidulafungin for 9 (7 to 15) days during
their stay in the intensive care unit. Additional anidulafungin
trough concentrations were measured in 15 patients, 2 (2 to 4)
concentrations per patient, and they ranged from 1.2 mg/liter to
4.7 mg/liter. Figure 1 shows the obtained concentration-time
curves. The measured anidulafungin maximum concentration of
drug in plasma (Cmax) was 4.6 (3.6 to 5.7) mg/liter, and the min-
imum concentration of drug in plasma (Cmin) was 2.1 (1.8 to 3.1)
mg/liter.
Pharmacokinetics. The observed AUC0–24 was 65.7 (57.3 to
85.0) mg · h/liter. The population pharmacokinetic parameters of
the developed model were as follows: CL, 1.39 0.488 liter/h/56
kg FFM;V1, 0.426 0.164 liter/kg LBMc;Q, 7.94 2.30 liter/h/56
kg FFM; V2, 0.514  0.226 liter/kg LBMc (each presented as the
populationmean the standard deviation). Themedian values of
the pharmacokinetic parameters of themodel and themodel dur-
ing cross-validation based on all concentration-time curves, are
presented in Table 1. The parameters of the cross-validation were
not significantly different from the parameters of the model. The
FIG 1 Concentration-time curves of the 20 critically ill patients receiving 100
mg anidulafungin once daily.
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residual error parameters were 0.048mg/liter (additive error) and
0.111 (proportional error). The predicted AUC0–24 values during
the cross-validation with the n 1 models were not significantly
different (P 0.254) from the values obtained with the developed
model.
Limited-sampling strategies. Table 2 shows the results of the
limited-sampling module of MWPharm using Bayesian analysis
for parameter estimation. The anidulafungin concentration mea-
sured 12 h after the start of the infusion seemed to be the most
suitable time point for predicting the AUC0–24 with an acceptable
bias and precision. The predicted AUC0–24 values during the
cross-validation with the n 1 models were not significantly dif-
ferent (P  0.422) from the values obtained with the developed
model. The mean ratio (90% CI) of the predicted exposures was
100.04% (99.67 to 100.40%).
Data from the limited-sampling strategies based on linear re-
gression analyses are presented in Table 2. The sampling time of
the most suitable strategy for predicting the AUC0–24 using linear
regression was also 12 h after the start of the infusion with anidu-
lafungin. The equation of the corresponding regression line,
which is illustrated in Fig. 2, was AUC0–24 3.8 24.1 · C (12).
The predicted AUC0–24 values during the cross-validation with
the n  1 regression were not significantly different (P  0.772)
from the values obtained with the complete regression. The mean
ratio (90% CI) of the predicted exposures was 99.97% (99.76 to
100.19%).
The Bland-Altman analyses of the correlation between the ob-
served AUC0–24 and the predicted AUC0–24 using the pharmaco-
kinetic model and the linear regression equation are shown in Fig.
3A andB, respectively. Themean ratios (90%CIs) of the predicted
versus the observed anidulafungin exposure were 99.03% (96.56
to 101.50%) for the pharmacokinetic model and 100.05% (98.97
to 101.12%) for the linear regression analysis.
External data set. Data were obtained from 47 healthy volun-
teers, 38 male and 9 female, with a median age of 24 (22 to 33)
years and a BMI of 24.2 (21.5 to 26.2) kg/m2. The observed anidu-
lafungin AUC0–24 was 109.8 (86.7 to 122.4) mg · h/liter. The
Bland-Altman analyses of the correlation between the observed
AUC0-24 and the predicted AUC0–24 using the pharmacokinetic
model and the linear regression equation are shown in Fig. 3C and
D. Themean ratios (90%CIs) of the predicted versus the observed
anidulafungin exposure were 95.39% (93.75 to 97.03%) for the
pharmacokinetic model and 101.62% (99.89 to 103.35%) for the
linear regression analysis.
Possible implications for clinical practice. Figure 4 illustrates
the specific clinical situations in which it can be necessary to de-
termine anidulafungin exposure. In most patients, anidulafungin
exposure will be sufficient after receiving the standard dose (i.e., a
loading dose of 200 mg on day one and continuing with a main-
tenance dose of 100 mg once daily). The anidulafungin AUC of
approximately one-quarter of the patients infectedwith aCandida
species with MICs of 0.016 mg/liter for Candida albicans and 0.03
mg/liter forCandida glabrata is expected to be insufficient. For the
very few patients with Candida species withMICs of 0.03 mg/liter
for C. albicans and 0.06 mg/liter for C. glabrata, the exposure in
most critically ill patients may be insufficient.
Figure 5 shows a pharmacokinetic simulation of the increased
maintenance dose of 170 mg for a 75-year-old patient (BMI, 24.7
kg/m2) with an AUC of 64.5 mg · h/liter after the standard dose of
100 mg after a loading dose of 200 mg. The predicted AUC0–24
after 5 doses of 170 mg is 109.7 mg · h/liter.
DISCUSSION
Wedemonstrate here that limited-sampling strategies can be used
to predict anidulafungin exposure with acceptable precision and
TABLE 1 AUC0–24 values and population pharmacokinetic model parameters from the developed model and from the n 1 models from the
cross-validation
Parametera Model Validation P value
AUC0–24 (mg · h/liter) 64.0 (55.3–84.2) 64.0 (55.3–84.2) 0.254
CL (liter/h/56 kg FFM) 1.26 (1.10–1.71) 1.26 (1.11–1.71) 0.062
V1 (liter/kg LBMc) 0.401 (0.338–0.529) 0.401 (0.335–0.530) 0.131
Q (liter/h/56 kg FFM) 7.79 (7.32–8.45) 7.81 (7.48–8.39) 0.550
V2 (liter/kg LBMc) 0.514 (0.439–0.657) 0.520 (0.442–0.659) 0.334
a AUC0–24, area under the concentration-time curve over a 24-h dosing interval; CL, clearance; FFM, fat-free mass; LBMc, lean body mass corrected; V1, central volume of
distribution; Q, intercompartmental clearance; V2, peripheral volume of distribution.
TABLE 2 Limited sampling strategies from the pharmacokinetic model






(%) R2 Bias (%)
RMSE
(%)
12 0.89 0.1 9 0.99 0.05 3
8 0.80 0.8 12 0.97 0.7 6
24 0.79 1.3 12 0.91 0.7 10
1.5, 12 0.93 1.2 7 0.99 0.04 3
8, 12 0.93 0.9 7 0.99 0.1 3
1.5, 12, 24 0.97 1.3 5 0.99 0.02 3
1.5, 8, 12, 24 0.98 1.5 4 0.99 0.1 2
FIG 2 The observed AUC0–24 versus the concentration measured 12 h after
the start of the anidulafungin infusion.
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bias. Anidulafungin exposure can be estimated with the concen-
tration from a single sample drawn 12 h after the start of infusion
by either linear regression or using a population pharmacokinetic
model.
This limited-sampling strategy can be advantageous for future
research, including investigating the AUC/MIC ratio in daily
practice and in specific clinical situations when the MIC is un-
known or close to the clinical breakpoint since only one sample is
required instead of a complete concentration-time curve. In the
case of possible insufficient exposure, anidulafungin doses can be
increased in a linear manner since anidulafungin exposure in-
creases proportionally to the dose (1). Simulation of a linearly
increased anidulafungin dose in our pharmacokinetic model sup-
ports this. Deviating from the standard dose is not included in the
FIG 3 Bland-Altman plots of the observed anidulafungin AUC0–24 versus the predicted AUC0–24 values with MWPharm (A) or regression analysis (B) for
critically ill patients (n  20) and Bland-Altman plots of the observed anidulafungin AUC0–24 versus the predicted AUC0–24 values with MWPharm (C) or
regression analysis (D) for the healthy volunteers (n 47).
FIG 4 The probability of target attainment versus the MIC for C. albicans (A) and C. glabrata (B) for critically ill patients. The bars represent the distribution of
MICs based on EUCAST data.
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summary of product characteristics, however. There has been lim-
ited experience with increased anidulafungin doses in patients
with Candida endocarditis. A double anidulafungin dose seemed
to be well tolerated (13). A decrease of the anidulafungin dose
seems currently unnecessary because adverse events are uncom-
mon but might be considered in the future to decrease costs when
more information is available about the AUC/MIC ratio in daily
practice.
We used cross-validation for our pharmacokinetic model and
linear regression analysis because this is an efficient method for
reliable validation and evaluation of the accuracy and precision of
limited-sampling strategies without the need for additional pa-
tients (14).
For anidulafungin, it appeared feasible to develop a limited-
sampling strategy based on linear regression, which has some ad-
vantages. This method is easy to use without extensive knowledge
or pharmacokinetic modeling software. The time point 12 h after
the start of the infusion appeared to be the optimal sampling
time for accurately estimating the anidulafungin exposure
based on the linear regression analysis and the Bayesian analy-
sis in MWPharm. This time point is convenient for daily prac-
tice in our intensive care units since this time point coincides
with the time for routine sampling in most cases.
The strength of this study is that the developed limited-sam-
pling strategies in critically ill patients were also investigated with
data from healthy volunteers. Accurately estimating the anidula-
fungin exposure appeared possible using linear regression and the
pharmacokineticmodel in critically ill patients and in healthy vol-
unteers. These two methods have their own advantages. Linear
regression analysis is simple and easy to use and does not require
pharmacokinetic software. However, limited sampling based on a
pharmacokinetic model is more flexible regarding sampling
times, and other data that can improve the predictive performance
can be incorporated.
In conclusion, this study shows that anidulafungin exposure
can be estimated accurately using a single blood sample drawn 12
h after the start of the infusion by using either linear regression or
a pharmacokinetic model in critically ill patients and in less-ill
patients, as reflected by healthy volunteers.
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